CRISPR-based platform pinpoints drivers of leukemia in patient cells

CRISPR-based platform pinpoints drivers of leukemia in patient cells

A new CRISPR-based tool that is directly used on patients' cancer cells can identify genes and regulatory elements driving acute myeloid leukemia (AML), an aggressive blood cancer affecting the bone marrow and blood. This first-of-its-kind approach reveals how individual patient cells respond to genetic changes and makes it easier to identify drug targets and understand why some cancers stop responding to treatment. The findings were published t…